查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1972676

碘-131同位素市場：依產品類型、應用、最終用途及通路分類－2026-2032年全球預測

Iodine-131 Isotope Market by Product Type, Application, End Use, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，碘-131 同位素市場價值將達到 7.453 億美元，到 2026 年將成長至 7.8867 億美元，到 2032 年將達到 10.822 億美元，複合年成長率為 5.47%。

主要市場統計數據
基準年 2025 7.453億美元
預計年份：2026年 7.8867億美元
預測年份 2032 1,082,200,000 美元
複合年成長率 (%) 5.47%

對碘-131的臨床意義、供應和監管趨勢以及營運重點進行策略概述，以支持短期相關人員的決策。

碘-131 仍然是一種核心放射性藥物，在腫瘤學和甲狀腺疾病治療中具有持續的臨床意義。近年來，其治療效用、供應鏈運作中的薄弱環節以及日益嚴格的監管審查引起了廣泛關注。這三個因素共同影響醫療服務提供者、生產者和支付方採購和臨床整合的方式。在此背景下，相關人員需要明確整合臨床適應症、生產方法和物流依賴關係，並將營運計畫與患者照護的優先事項保持一致。

這定義了治療創新、供應韌性、監管改革和營運現代化如何共同改變碘-131的使用和供應模式。

由於治療、給藥和監管方面的創新，碘-131領域正經歷變革性的變化。在治療方面，標靶給藥方法和聯合治療的整合正在重塑臨床通訊協定，並影響醫療機構多樣化的需求。同時，放射性藥物分發實踐和自動化分發技術的進步正在改變醫療機構管理劑量準確性、職業安全和處理能力的方式。

本研究評估了美國在 2025 年徵收的關稅對碘-131的採購、分銷經濟和臨床連續性計劃的營運和戰略影響。

2025年關稅的徵收和貿易政策的變化，已在放射性藥物原料和碘-131成品的現有供應鏈中造成了明顯的營運摩擦，促使採購團隊重新評估其籌資策略和總到岸成本結構。雖然關稅只是一項政策工具，但其影響卻波及生產經濟、庫存管理實踐以及跨境臨床供應等各個方面，因此生產商和供應商都需要採取戰術性和戰略應對措施。

實際的細分分析揭示了應用重點、產品形式、臨床最終用戶和通路如何共同塑造部署和商業化選擇。

對市場細分的深入分析闡明了臨床應用、產品配方、終端用戶環境和通路如何全面決定產品的採用模式和營運重點。按應用領域分類，癌症治療、醫學影像和甲狀腺治療的臨床需求各不相同。在癌症治療領域，聯合治療和標靶治療通訊協定又有差異，每種方案都對應不同的給藥方案、頻率需求和醫護人員準備要求。

從區域觀點來看，我們將詳細分析美洲、歐洲、中東、非洲和亞太地區的准入便利因素、監管差異、供應基地和投資環境。

區域趨勢對碘-131的取得、監管複雜性和供應結構起著至關重要的作用。在美洲，完善的臨床網路和成熟的放射性藥物分發能力支持其在三級醫療機構的廣泛應用；然而，地理分​​散導致部分地區獲取受限，因此需要進行物流創新並採用中心輻射式分銷模式。該地區的需求模式受到不斷變化的臨床指南和報銷政策的影響，這些因素決定了治療用途和診斷用途之間的優先順序。

主要企業層面深入了解製造實力、以服務為中心的差異化、策略夥伴關係以及塑造碘-131領導地位的競爭優勢。

在企業層面，發展趨勢體現在核心製造能力、專業放射化學技術和服務導向能力的整合，這些因素決定了企業的競爭地位。主要企業優先考慮穩定採購前驅材料、投資建置符合GMP規範的放射性藥物生產線，並實施先進的品質管理系統以滿足監管要求。同時，一些企業透過提供承包放射性藥物服務、臨床試驗支援和物流夥伴關係等增值服務來減輕終端用戶的負擔，從而實現差異化競爭。

為產業領導者提供切實可行的優先建議，以加強供應鏈韌性、加速臨床部署並降低監管和營運風險。

產業領導者應共同採取一系列戰術性和策略行動，以增強供應鏈韌性，支持臨床應用，並應對監管和成本壓力。首先，應優先投資於供應鏈的透明度和冗餘性，具體措施包括認證替代前體供應商和製定應急生產計畫。整合以場景為基礎的庫存管理將減少服務中斷，保障臨床工作的連續性。其次，應透過培訓、標準化製備通訊協定和資本資金籌措模式，支持膠囊劑、注射和液體製劑的工作流程，使產品劑型策略與醫療服務提供者的能力相符。

高度透明且可重複的調查方法：結合與專家的直接對話、整合二手證據、實地檢驗和分析三角測量。

本分析的調查方法結合了結構化的專家訪談和全面的二手證據審查，以確保研究的深度和有效性。主要訪談對象包括臨床醫生、放射性藥物管理人員、生產管理人員和物流專家，他們提供了關於臨床通訊協定、營運限制和供應鏈緊急應變計畫的直接見解。除了這些定性訪談外，還進行了現場考察和流程審核，以觀察實際的藥品分發流程和低溫運輸操作。

為了向相關人員提供了解碘-131現狀的指南，本文檔提出了一個簡明的結論，整合了策略要求、營運風險和機會創造途徑。

總之，碘-131佔據著一個關鍵的市場定位，治療需求與物流複雜性在此交匯，因此相關人員需要採取綜合策略，以確保患者能夠持續獲得治療。治療創新、供應鏈重組以及日益嚴格的監管要求，既帶來了風險，也帶來了機會。那些積極提升生產可靠性、調整產品形式以適應臨床工作流程並與監管機構和供應商合作的機構，將更有利於創造價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：碘-131同位素市場：依產品類型分類

  • 膠囊
  • 注射藥物
    • 預填充式注射器
    • 管瓶
  • 液體溶液

第9章：碘-131同位素市場：依應用領域分類

  • 癌症治療
    • 聯合治療
    • 標靶治療
  • 醫學影像診斷
  • 甲狀腺治療

第10章：碘-131同位素市場：依最終用途分類

  • 診斷中心
  • 醫院
  • 研究機構

第11章 碘-131同位素市場：依分銷管道分類

  • 直銷
  • 銷售代理

第12章 碘-131同位素市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 碘-131同位素市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 碘-131同位素市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國碘-131同位素市場

第16章：中國碘-131同位素市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Advanced Accelerator Applications SA
  • China Isotope & Radiation Corporation
  • Curium Pharma SAS
  • Eckert & Ziegler Radiopharma GmbH
  • Institute for Radioelements SCRL
  • Jubilant Pharma Limited
  • Lantheus Holdings, Inc.
  • Mallinckrodt plc
  • Nordion Inc.
  • NorthStar Medical Radioisotopes LLC
  • NorthStar Medical Radioisotopes LLC
Product Code: MRR-9A6A6F297712

The Iodine-131 Isotope Market was valued at USD 745.30 million in 2025 and is projected to grow to USD 788.67 million in 2026, with a CAGR of 5.47%, reaching USD 1,082.20 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 745.30 million
Estimated Year [2026] USD 788.67 million
Forecast Year [2032] USD 1,082.20 million
CAGR (%) 5.47%

Strategic overview of iodine-131 clinical relevance, supply and regulatory dynamics, and operational priorities that inform near-term stakeholder decision making

Iodine-131 remains a cornerstone radiopharmaceutical with enduring clinical relevance across oncology and thyroid care. Recent years have seen an intensification of attention on its therapeutic utility, operational fragility in supply chains, and regulatory scrutiny that together shape how providers, manufacturers, and payers approach procurement and clinical integration. Against this backdrop, stakeholders require a clear synthesis of clinical indications, manufacturing modalities, and logistical dependencies to align operational plans with patient care priorities.

This introduction situates iodine-131 within a broader convergence of therapeutic innovation and health system resource constraints. It highlights emerging procedural norms and technological enablers that influence utilization patterns, while emphasizing supply continuity as a strategic risk that demands proactive mitigation. Moreover, by framing current dynamics in relation to evolving regulatory expectations and clinical trial activity, the introduction prepares readers to navigate trade-offs between access, safety, and scalability.

In practical terms, this section orients leaders to the core levers that will determine near-term decision making: clinical demand drivers, manufacturing and distribution realities, and the regulatory pathways shaping product availability. It establishes a foundation for the deeper analyses that follow and underscores the imperative of integrated, cross-functional responses to sustain patient access and institutional readiness.

Defining how therapeutic innovation, supply resilience, regulatory reform, and operational modernization are jointly transforming iodine-131 utilization and delivery models

The iodine-131 landscape is undergoing transformative shifts driven by innovation at the therapeutic, operational, and regulatory margins. On the therapeutic front, integration of targeted delivery approaches and combination regimens is reshaping clinical protocols and influencing demand heterogeneity across care settings. At the same time, developments in radiopharmacy practice and automated dispensing technologies are altering how facilities manage dosing accuracy, occupational safety, and throughput.

Operationally, supply chain resilience has moved from a desirable attribute to a core strategic objective. Multi-node sourcing strategies, investments in onshore or regional production capacity, and strengthened cold-chain capabilities are becoming essential responses to episodic interruptions. Concurrently, regulators are tightening oversight around radiopharmaceutical manufacturing standards and traceability, prompting organizations to increase compliance investments and to adopt more robust quality management systems.

These shifts are not isolated; they interact in ways that create new value pathways. For instance, therapeutic innovations that reduce required dose or frequency can ease logistical pressure, while improved distribution practices accelerate clinical access and reduce waste. Therefore, leaders must consider cross-functional interventions that link clinical development, operations, and regulatory engagement to realize sustained improvements in availability and patient outcomes.

Assessing the operational and strategic consequences of United States tariffs in 2025 on iodine-131 sourcing, distribution economics, and clinical continuity planning

The imposition of tariffs and trade policy changes in 2025 introduced measurable operational friction into established supply chains for radiopharmaceutical inputs and finished iodine-131 products, prompting procurement teams to reassess sourcing strategies and total landed cost structures. Although tariffs are a single policy lever, their effects cascade across manufacturing economics, inventory practices, and cross-border clinical provisioning, necessitating tactical and strategic responses from producers and providers alike.

In immediate operational terms, organizations adjusted procurement rhythms, increased holding inventory where feasible, and explored alternate sourcing geographies to maintain continuity of care. These actions, in turn, reshaped distribution timelines and elevated the importance of contractual flexibility and inventory visibility. From a strategic perspective, the tariff environment accelerated conversations about regional production capacity and vertical integration to reduce exposure to transnational cost shocks.

Importantly, these responses varied by institutional capability. Larger health systems and specialized manufacturers with deep supply networks adapted more rapidly through diversified procurement and inventory management, while smaller centers faced greater pressure to negotiate supplier terms or to collaborate through purchasing consortia. Going forward, resilience planning must factor tariff volatility into capital allocation, contractual design, and collaborative frameworks that preserve patient access amid evolving trade dynamics.

Actionable segmentation insights revealing how application focus, product form, clinical end users, and distribution pathways combine to shape deployment and commercialization choices

A granular view of market segmentation clarifies how clinical application, product formulation, end-user environment, and distribution pathways collectively determine adoption patterns and operational priorities. When examined by application, clinical demand differentiates across cancer therapy, medical imaging, and thyroid treatment; within cancer therapy, there is further delineation between combination therapy approaches and targeted therapy protocols, each driving distinct dosing regimens, frequency expectations, and provider readiness requirements.

Product-type segmentation further refines logistical and regulatory considerations. Capsules, injectable formats, and liquid solutions each impose unique handling and dispensing protocols; specifically, injectable formats bifurcate into prefilled syringe presentations and vial-based delivery, with implications for sterility controls, occupational safety procedures, and on-site preparation workflows. These product distinctions dictate cold-chain needs, pharmacy staffing models, and capital investments in dispensing equipment.

End-use contexts-diagnostic centers, hospitals, and research institutes-exhibit varied operational capabilities and procurement models that influence inventory practices and clinical throughput. Distribution channel dynamics, whether through direct sales relationships or distributor networks, shape contractual terms, lead-time expectations, and the scope of after-sales support. Taken together, these segmentation lenses inform targeted go-to-market strategies, clinical training priorities, and infrastructure investments that align product form and channel to institutional capability.

Tailored regional perspectives highlighting access drivers, regulatory variation, supply hubs, and investment climates across Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics play a decisive role in access, regulatory complexity, and supply architecture for iodine-131. In the Americas, robust clinical networks and established radiopharmacy capabilities support concentrated usage in tertiary centers, but geographic dispersion creates pockets of access constraint that require logistical innovation and hub-and-spoke distribution models. Demand patterns in this region are influenced by evolving clinical guidelines and reimbursement practices that drive prioritization of therapeutic versus diagnostic use cases.

Moving to Europe, Middle East & Africa, regulatory fragmentation and variable infrastructure maturity create heterogeneity in clinical adoption and supply reliability. In several European markets, well-established nuclear medicine programs coexist with regulatory frameworks that emphasize pharmacovigilance and manufacturing traceability, whereas parts of the Middle East and Africa are actively investing in capacity building to reduce import dependence and to enhance local clinical capabilities. Cross-border collaboration and regional centers of excellence are emerging mechanisms to address uneven access.

Across Asia-Pacific, rapid clinical expansion in oncology services, significant investment in local manufacturing, and a dynamic regulatory environment are accelerating adoption in both public and private systems. However, disparities in facility-level readiness and cold-chain infrastructure mean that regional strategies must be calibrated to local logistical realities. Collectively, regional variation underscores the need for differentiated commercial approaches and targeted capacity-building initiatives that respect regulatory and operational context.

Key company-level insights into manufacturing strengths, service-centric differentiation, strategic alliances, and competitive levers shaping iodine-131 leadership

Company-level dynamics reflect a blend of core manufacturing competencies, specialized radiochemistry expertise, and service-oriented capabilities that determine competitive positioning. Leading manufacturers have prioritized secure sourcing of precursor materials, investments in GMP-compliant radiopharmaceutical production lines, and implementation of advanced quality systems to satisfy regulatory scrutiny. Concurrently, some organizations have differentiated through extended service offerings such as turnkey radiopharmacy operations, clinical trial support, and logistics partnerships that reduce friction for end users.

Contract manufacturing organizations and specialized nuclear medicine firms have expanded collaboration models with healthcare providers to offer integrated solutions that combine supply, training, and onsite preparation. This shift from pure product supply toward service-enabled partnerships enhances stickiness with major hospital systems and diagnostic networks. At the same time, smaller niche players continue to innovate in formulation and dispensing technologies, offering modular solutions that target specific clinical workflows or resource-constrained settings.

Strategic alliances, including partnerships with logistics specialists and clinical networks, have become common as companies seek to manage distribution complexity and to scale access. Intellectual property management, regulatory track records, and the ability to execute reliable batch production remain central determinants of competitive advantage in this specialized domain.

Practical and prioritized recommendations for industry leaders to reinforce supply resilience, accelerate clinical adoption, and mitigate regulatory and operational risks

Industry leaders should adopt a coordinated set of tactical and strategic actions to strengthen supply resilience, support clinical uptake, and manage regulatory and cost pressures. First, prioritize investments in supply chain visibility and redundancy by qualifying alternate suppliers of precursors and by developing contingency production plans; integrating scenario-based inventory management will reduce service disruptions and protect clinical continuity. Second, align product-format strategies with provider capabilities by supporting capsule, injectable, and liquid solution workflows through training, standardized preparation protocols, and equipment financing models.

Third, engage proactively with regulatory agencies and professional societies to shape pragmatic compliance pathways that safeguard patient safety while reducing administrative friction. Fourth, pursue collaborative service models that bundle supply with technical assistance-such as on-site radiopharmacy consulting, dosing optimization, and safety training-to increase value to end users and to deepen commercial relationships. Fifth, explore regional manufacturing partnerships or licensing arrangements to reduce cross-border exposure and to leverage local regulatory approvals for faster clinical deployment.

Finally, invest in data-driven post-market surveillance and real-world evidence generation that documents clinical outcomes and supports payer conversations. These measures, taken together, will improve predictability, enhance clinical integration, and create defensible competitive positioning in a resource-constrained, highly regulated environment.

Transparent and reproducible research methodology blending primary expert engagement, secondary evidence synthesis, site-level validation, and analytical triangulation

The research methodology underpinning this analysis combined structured primary engagement with domain experts and a comprehensive secondary evidence review to ensure depth and validity. Primary inputs included interviews with clinicians, radiopharmacy managers, manufacturing leaders, and logistics specialists who provided firsthand perspectives on clinical protocols, operational constraints, and supply contingencies. These qualitative engagements were complemented by site visits and process audits to observe dispensing workflows and cold-chain practices in situ.

Secondary research synthesized regulatory guidance, peer-reviewed clinical literature, manufacturing standards, and publicly available clinical trial registries to triangulate trends and to validate operational hypotheses. Additionally, patent landscapes and technical white papers informed assessments of formulation and dispensing innovations. Analytical frameworks emphasized cross-functional triangulation, ensuring that clinical demand signals, production realities, and distribution constraints were considered in concert.

Validation steps included peer review from independent subject-matter experts and cross-checks against published clinical guidelines and regulatory documents. Where possible, findings were corroborated through multiple sources to reduce bias. The methodology prioritized transparency, reproducibility, and a clear audit trail for key assertions, enabling stakeholders to understand the evidence base behind strategic recommendations.

Concise conclusion synthesizing strategic imperatives, operational risks, and opportunity pathways to guide stakeholders through the iodine-131 landscape

In conclusion, iodine-131 occupies a critical niche at the intersection of therapeutic need and logistical complexity, and stakeholders must adopt integrated strategies to ensure sustained patient access. The convergence of therapeutic innovation, supply chain rebalancing, and heightened regulatory expectations creates both risk and opportunity; organizations that proactively shore up manufacturing reliability, align product forms to clinical workflows, and engage collaboratively with regulators and providers will be best positioned to deliver value.

Moreover, regional diversity in infrastructure and regulatory approaches requires tailored responses that combine targeted investments with partnership models that scale capability efficiently. Companies that develop service-enabled offerings and that invest in real-world evidence to substantiate clinical benefits will enhance adoption and deepen institutional relationships. Finally, resilient procurement practices, scenario-based planning for policy shifts, and investments in operational excellence will collectively reduce vulnerability to supply shocks and policy changes.

Taken together, these priorities form a pragmatic roadmap for sustaining and expanding access to iodine-131 therapies and diagnostics while managing cost and compliance considerations in an increasingly complex global environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Iodine-131 Isotope Market, by Product Type

  • 8.1. Capsule
  • 8.2. Injectable
    • 8.2.1. Prefilled Syringe
    • 8.2.2. Vial
  • 8.3. Liquid Solution

9. Iodine-131 Isotope Market, by Application

  • 9.1. Cancer Therapy
    • 9.1.1. Combination Therapy
    • 9.1.2. Targeted Therapy
  • 9.2. Medical Imaging
  • 9.3. Thyroid Treatment

10. Iodine-131 Isotope Market, by End Use

  • 10.1. Diagnostic Centers
  • 10.2. Hospitals
  • 10.3. Research Institutes

11. Iodine-131 Isotope Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Distributors

12. Iodine-131 Isotope Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Iodine-131 Isotope Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Iodine-131 Isotope Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Iodine-131 Isotope Market

16. China Iodine-131 Isotope Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Advanced Accelerator Applications S.A.
  • 17.6. China Isotope & Radiation Corporation
  • 17.7. Curium Pharma SAS
  • 17.8. Eckert & Ziegler Radiopharma GmbH
  • 17.9. Institute for Radioelements SCRL
  • 17.10. Jubilant Pharma Limited
  • 17.11. Lantheus Holdings, Inc.
  • 17.12. Mallinckrodt plc
  • 17.13. Nordion Inc.
  • 17.14. NorthStar Medical Radioisotopes LLC
  • 17.15. NorthStar Medical Radioisotopes LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IODINE-131 ISOTOPE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IODINE-131 ISOTOPE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES IODINE-131 ISOTOPE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA IODINE-131 ISOTOPE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY LIQUID SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY LIQUID SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY LIQUID SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY MEDICAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY MEDICAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY MEDICAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY THYROID TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY THYROID TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY THYROID TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS IODINE-131 ISOTOPE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. GCC IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 121. GCC IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. GCC IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. GCC IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 124. GCC IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. G7 IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 142. G7 IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. G7 IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. G7 IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 145. G7 IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. NATO IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 149. NATO IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. NATO IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. NATO IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 152. NATO IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES IODINE-131 ISOTOPE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA IODINE-131 ISOTOPE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)